Analysts Set Sensus Healthcare, Inc. (NASDAQ:SRTS) Target Price at $6.88

Shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) have been given a consensus rating of “Moderate Buy” by the seven research firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $6.8750.

SRTS has been the subject of several research reports. Citigroup restated a “buy” rating on shares of Sensus Healthcare in a report on Friday, May 8th. Wall Street Zen lowered shares of Sensus Healthcare from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Maxim Group decreased their price objective on shares of Sensus Healthcare from $8.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Alliance Global Partners initiated coverage on shares of Sensus Healthcare in a research report on Friday, March 6th. They issued a “buy” rating and a $7.50 target price on the stock. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sensus Healthcare in a research report on Tuesday, April 21st.

Sensus Healthcare Trading Down 0.9%

Shares of NASDAQ SRTS opened at $3.32 on Friday. Sensus Healthcare has a 12 month low of $2.82 and a 12 month high of $5.92. The firm has a market capitalization of $54.65 million, a PE ratio of -7.06 and a beta of 1.19. The firm has a fifty day simple moving average of $3.98 and a two-hundred day simple moving average of $4.17.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.04). Sensus Healthcare had a negative return on equity of 15.79% and a negative net margin of 34.50%.The company had revenue of $3.39 million during the quarter, compared to the consensus estimate of $5.32 million.

Institutional Trading of Sensus Healthcare

A number of hedge funds and other institutional investors have recently modified their holdings of the business. State Street Corp grew its position in shares of Sensus Healthcare by 5.2% in the 4th quarter. State Street Corp now owns 69,252 shares of the company’s stock worth $276,000 after buying an additional 3,400 shares during the period. Geode Capital Management LLC grew its position in shares of Sensus Healthcare by 2.5% in the 2nd quarter. Geode Capital Management LLC now owns 153,917 shares of the company’s stock worth $730,000 after buying an additional 3,766 shares during the period. Sachetta LLC grew its position in shares of Sensus Healthcare by 6.8% in the 4th quarter. Sachetta LLC now owns 148,508 shares of the company’s stock worth $591,000 after buying an additional 9,500 shares during the period. Mindset Wealth Management LLC grew its position in shares of Sensus Healthcare by 28.1% in the 3rd quarter. Mindset Wealth Management LLC now owns 50,100 shares of the company’s stock worth $157,000 after buying an additional 11,000 shares during the period. Finally, Opes Wealth Management LLC purchased a new stake in shares of Sensus Healthcare in the 3rd quarter worth about $50,000. 25.30% of the stock is owned by hedge funds and other institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.